S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins (2013/9/10)|
|Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901 ()|
|Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment of Type 1 Diabetes ()|
|Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes ()|
|Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013 (2013/9/25)|
|Oramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins (2013/10/3)|
|Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule (2013/11/12)|
|Oramed's Platform Technology in Oral Delivery of Proteins Receives Patent in Russia (2013/9/17)|
|Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel (2013/12/10)|
|Oramed Receives Patent in the European Union for the Oral Delivery of Insulin (2013/11/19)|
Click above to view more mutual fund data and stats for ormp - Oramed Pharmaceuticals Inc.